ArticlebioRxiv : the preprint server for biology2025
SETD2 suppresses tumorigenesis in a KRAS
Ricardo J Mack, Natasha M Flores, Geoffrey C Fox, Hanyang Dong, Metehan Cebeci, Simone Hausmann, Tourkian Chasan, Jill M Dowen, Brian D Strahl, Pawel K Mazur and 1 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Natasha M FloresDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Geoffrey C FoxCurriculum in Genetics & Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-5898-0847 Hanyang DongDepartment of Biology, Stanford University, Stanford CA 94305 USA.
Metehan CebeciDepartment of Biology, Stanford University, Stanford CA 94305 USA.
Simone HausmannDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Tourkian ChasanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jill M DowenCurriculum in Genetics & Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Brian D StrahlCurriculum in Genetics & Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-4947-6259 Pawel K MazurDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-5820-8344 Funding
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MMechanisms of chromatin and transcriptional regulationR35GM126900 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian D Strahl · 2018 to 2026
$5.5MNRSA in GeneticsT32GM135128 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Daniel J McKay, JEFF J. SEKELSKY · 2020 to 2026
$5.1MFunction of Protein Methylation in Chromatin and Signaling RegulationR35GM139569 · NIGMS · STANFORD UNIVERSITY · PI Or P. Gozani · 2021 to 2026
$4.0MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MTherapeutic Targeting of NSD2 in Lung AdenocarcinomaR01CA272844 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6MMechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancerR01CA272843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD, Pawel K. Mazur · 2023 to 2026
$2.6MRole of NSD3 in regulation of cancer pathogenesisR01CA278940 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6MRole of SETD5 in Chromatin Regulation and TumorigenesisR01CA236949 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2019 to 2023
$1.9MThe role of genome folding in regulating gene expression and chromatin stateR35GM152103 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jill Dowen · 2024 to 2026
$1.3MNCI NIH HHS R01 CA236949NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA272843NCI NIH HHS R01 CA272844NCI NIH HHS R01 CA278940NCI NIH HHS T32 CA009302NIGMS NIH HHS R35 GM126900NIGMS NIH HHS R35 GM139569NIGMS NIH HHS R35 GM152103NIGMS NIH HHS T32 GM135128
6 · The paper itselfAbstract
Histone H3 trimethylation at lysine 36 (H3K36me3) is a key chromatin modification that regulates fundamental physiologic and pathologic processes. In humans, SETD2 is the only known enzyme that catalyzes H3K36me3 in somatic cells and is implicated in tumor suppression across multiple cancer types. While there is considerable crosstalk between the SETD2-H3K36me3 axis and other epigenetic modifications, much remains to be understood. Here, we show that SETD2 functions as a potent tumor suppressor in a KRAS
Identifiers
PMID40462961
PMCPMC12132414
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390